Development, preclinical safety, formulation, and stability of clinical grade bevacizumab-800CW, a new near infrared fluorescent imaging agent for first in human use von ter Weele, Eva J., Terwisscha van Scheltinga, Anton G.T., Linssen, Matthijs D., Nagengast, Wouter B., Lindner, Ingo, Jorritsma-Smit, Annelies, de Vries, Elisabeth G.E., Kosterink, Jos G.W., Lub-de Hooge, Marjolijn N.

Volltext

Roadmap for the Development and Clinical Translation of Optical Tracers Cetuximab-800CW and Trastuzumab-800CW von Linssen, Matthijs D, Ter Weele, Eva J, Allersma, Derk P, Lub-de Hooge, Marjolijn N, van Dam, Gooitzen M, Jorritsma-Smit, Annelies, Nagengast, Wouter B

Volltext

ImmunoPET with Anti-Mesothelin Antibody in Patients with Pancreatic and Ovarian Cancer before Anti-Mesothelin Antibody-Drug Conjugate Treatment von Lamberts, Laetitia E, Menke-van der Houven van Oordt, Catharina W, ter Weele, Eva J, Bensch, Frederike, Smeenk, Michiel M, Voortman, Johannes, Hoekstra, Otto S, Williams, Simon P, Fine, Bernard M, Maslyar, Daniel, de Jong, Johan R, Gietema, Jourik A, Schröder, Carolien P, Bongaerts, Alphons H H, Lub-de Hooge, Marjolijn N, Verheul, Henk M W, Sanabria Bohorquez, Sandra M, Glaudemans, Andor W J M, de Vries, Elisabeth G E

Volltext

Imaging the distribution of an antibody-drug conjugate constituent targeting mesothelin with ⁸⁹Zr and IRDye 800CW in mice bearing human pancreatic tumor xenografts von ter Weele, Eva J, Terwisscha van Scheltinga, Anton G T, Kosterink, Jos G W, Pot, Linda, Vedelaar, Silke R, Lamberts, Laetitia E, Williams, Simon P, Lub-de Hooge, Marjolijn N, de Vries, Elisabeth G E

Volltext

Abstract 2659: Imaging human pancreatic tumor xenografts with 89Zr-labeled anti-mesothelin antibody von ter Weele, Eva J., Lub-de Hooge, Marjolijn N., Maslyar, Daniel, Terwisscha van Scheltinga, Anton G.T., Kosterink, Jos G.W., de Vries, Elisabeth G.E., Williams, Simon P.

Volltext